Toppgene analysis for Wikipedia protein communities, toppgene analysis, cc82_11, positive side

Go To Start Page
Input Parameters [Show Detail]
Training Results [Expand All] [Download All] [Sparse Matrix]
Display pValues and Scores as Table row limit

1: GO: Molecular Function [Display Chart] 11 input genes in category / 64 annotations before applied cutoff / 18661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0002039 p53 binding 8.888E-6 5.688E-4 2.698E-3 5.688E-4 3 72
2 GO:1990841 promoter-specific chromatin binding 4.276E-5 1.368E-3 6.490E-3 2.736E-3 2 17
3 GO:0050681 androgen receptor binding 2.558E-4 5.457E-3 2.589E-2 1.637E-2 2 41
4 GO:0003713 transcription coactivator activity 6.786E-4 1.086E-2
5.151E-2
 4.343E-2 3 310
5 GO:0055105 ubiquitin-protein transferase inhibitor activity 1.179E-3 1.283E-2
6.087E-2
7.543E-2
 1 2
6 GO:0035258 steroid hormone receptor binding 1.203E-3 1.283E-2
6.087E-2
7.699E-2
 2 89
7 GO:0005094 Rho GDP-dissociation inhibitor activity 1.767E-3 1.616E-2
7.666E-2
1.131E-1
 1 3
8 GO:0047485 protein N-terminus binding 2.066E-3 1.653E-2
7.840E-2
1.322E-1
 2 117
9 GO:0035257 nuclear hormone receptor binding 3.866E-3 2.565E-2
1.217E-1
2.474E-1
 2 161
10 GO:0001047 core promoter binding 4.008E-3 2.565E-2
1.217E-1
2.565E-1
 2 164
11 GO:0097371 MDM2/MDM4 family protein binding 4.707E-3 2.647E-2
1.256E-1
3.012E-1
 1 8
12 GO:0051427 hormone receptor binding 4.963E-3 2.647E-2
1.256E-1
3.176E-1
 2 183
13 GO:0019887 protein kinase regulator activity 5.616E-3 2.714E-2
1.288E-1
3.594E-1
 2 195
14 GO:0019207 kinase regulator activity 6.847E-3 2.714E-2
1.288E-1
4.382E-1
 2 216
15 GO:0004861 cyclin-dependent protein serine/threonine kinase inhibitor activity 7.053E-3 2.714E-2
1.288E-1
4.514E-1
 1 12
16 GO:0008432 JUN kinase binding 7.638E-3 2.714E-2
1.288E-1
4.889E-1
 1 13
17 GO:0005092 GDP-dissociation inhibitor activity 7.638E-3 2.714E-2
1.288E-1
4.889E-1
 1 13
18 GO:0035497 cAMP response element binding 7.638E-3 2.714E-2
1.288E-1
4.889E-1
 1 13
19 GO:0003714 transcription corepressor activity 8.059E-3 2.714E-2
1.288E-1
5.157E-1
 2 235
20 GO:0055106 ubiquitin-protein transferase regulator activity 8.809E-3 2.819E-2
1.337E-1
5.638E-1
 1 15
21 GO:0055103 ligase regulator activity 9.394E-3 2.863E-2
1.358E-1
6.012E-1
 1 16
22 GO:0031625 ubiquitin protein ligase binding 1.075E-2 3.076E-2
1.459E-1
6.880E-1
 2 273
23 GO:0044389 ubiquitin-like protein ligase binding 1.105E-2 3.076E-2
1.459E-1
7.074E-1
 2 277
24 GO:0019789 SUMO transferase activity 1.464E-2 3.905E-2
1.852E-1
9.371E-1
 1 25
25 GO:0030291 protein serine/threonine kinase inhibitor activity 1.755E-2 4.492E-2
2.131E-1
1.000E0
 1 30
26 GO:0051059 NF-kappaB binding 2.044E-2 4.983E-2
2.364E-1
1.000E0
 1 35
27 GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity 2.102E-2 4.983E-2
2.364E-1
1.000E0
 1 36
Show 22 more annotations

2: GO: Biological Process [Display Chart] 11 input genes in category / 571 annotations before applied cutoff / 18623 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0007050 cell cycle arrest 2.239E-9 6.605E-7 4.574E-6 1.279E-6 6 247
2 GO:0045786 negative regulation of cell cycle 2.314E-9 6.605E-7 4.574E-6 1.321E-6 7 484
3 GO:1901990 regulation of mitotic cell cycle phase transition 1.017E-8 1.935E-6 1.340E-5 5.806E-6 6 318
4 GO:1901987 regulation of cell cycle phase transition 1.463E-8 1.974E-6 1.367E-5 8.356E-6 6 338
5 GO:1901991 negative regulation of mitotic cell cycle phase transition 1.888E-8 1.974E-6 1.367E-5 1.078E-5 5 159
6 GO:0007093 mitotic cell cycle checkpoint 2.074E-8 1.974E-6 1.367E-5 1.184E-5 5 162
7 GO:1901988 negative regulation of cell cycle phase transition 2.641E-8 2.154E-6 1.492E-5 1.508E-5 5 170
8 GO:0045930 negative regulation of mitotic cell cycle 1.072E-7 7.444E-6 5.156E-5 6.123E-5 5 225
9 GO:0071158 positive regulation of cell cycle arrest 1.302E-7 7.444E-6 5.156E-5 7.432E-5 4 85
10 GO:0000075 cell cycle checkpoint 1.304E-7 7.444E-6 5.156E-5 7.444E-5 5 234
11 GO:0010948 negative regulation of cell cycle process 1.479E-7 7.677E-6 5.317E-5 8.444E-5 5 240
12 GO:0000082 G1/S transition of mitotic cell cycle 1.706E-7 8.119E-6 5.623E-5 9.743E-5 5 247
13 GO:0044843 cell cycle G1/S phase transition 2.079E-7 8.773E-6 6.076E-5 1.187E-4 5 257
14 GO:0090068 positive regulation of cell cycle process 2.160E-7 8.773E-6 6.076E-5 1.233E-4 5 259
15 GO:2000134 negative regulation of G1/S transition of mitotic cell cycle 2.313E-7 8.773E-6 6.076E-5 1.321E-4 4 98
16 GO:0044773 mitotic DNA damage checkpoint 2.612E-7 8.773E-6 6.076E-5 1.491E-4 4 101
17 GO:1902807 negative regulation of cell cycle G1/S phase transition 2.612E-7 8.773E-6 6.076E-5 1.491E-4 4 101
18 GO:0044774 mitotic DNA integrity checkpoint 3.295E-7 9.767E-6 6.764E-5 1.882E-4 4 107
19 GO:0071156 regulation of cell cycle arrest 3.421E-7 9.767E-6 6.764E-5 1.953E-4 4 108
20 GO:0030330 DNA damage response, signal transduction by p53 class mediator 3.421E-7 9.767E-6 6.764E-5 1.953E-4 4 108
21 GO:0042770 signal transduction in response to DNA damage 5.583E-7 1.518E-5 1.051E-4 3.188E-4 4 122
22 GO:0071930 negative regulation of transcription involved in G1/S transition of mitotic cell cycle 9.513E-7 2.450E-5 1.697E-4 5.432E-4 2 3
23 GO:0045787 positive regulation of cell cycle 9.867E-7 2.450E-5 1.697E-4 5.634E-4 5 352
24 GO:2000045 regulation of G1/S transition of mitotic cell cycle 1.146E-6 2.727E-5 1.889E-4 6.545E-4 4 146
25 GO:0000077 DNA damage checkpoint 1.419E-6 3.240E-5 2.244E-4 8.100E-4 4 154
26 GO:1902806 regulation of cell cycle G1/S phase transition 1.494E-6 3.280E-5 2.272E-4 8.528E-4 4 156
27 GO:0031570 DNA integrity checkpoint 1.823E-6 3.856E-5 2.671E-4 1.041E-3 4 164
28 GO:0043550 regulation of lipid kinase activity 3.534E-6 7.207E-5 4.991E-4 2.018E-3 3 53
29 GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest 5.689E-6 1.052E-4 7.284E-4 3.248E-3 3 62
30 GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint 5.971E-6 1.052E-4 7.284E-4 3.410E-3 3 63
31 GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint 5.971E-6 1.052E-4 7.284E-4 3.410E-3 3 63
32 GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint 6.263E-6 1.052E-4 7.284E-4 3.576E-3 3 64
33 GO:0072413 signal transduction involved in mitotic cell cycle checkpoint 6.263E-6 1.052E-4 7.284E-4 3.576E-3 3 64
34 GO:1902402 signal transduction involved in mitotic DNA damage checkpoint 6.263E-6 1.052E-4 7.284E-4 3.576E-3 3 64
35 GO:0072422 signal transduction involved in DNA damage checkpoint 6.874E-6 1.090E-4 7.551E-4 3.925E-3 3 66
36 GO:0072401 signal transduction involved in DNA integrity checkpoint 6.874E-6 1.090E-4 7.551E-4 3.925E-3 3 66
37 GO:0072395 signal transduction involved in cell cycle checkpoint 7.194E-6 1.110E-4 7.689E-4 4.108E-3 3 67
38 GO:0031571 mitotic G1 DNA damage checkpoint 9.322E-6 1.365E-4 9.452E-4 5.323E-3 3 73
39 GO:0044819 mitotic G1/S transition checkpoint 9.322E-6 1.365E-4 9.452E-4 5.323E-3 3 73
40 GO:0044783 G1 DNA damage checkpoint 9.713E-6 1.387E-4 9.602E-4 5.546E-3 3 74
41 GO:0072331 signal transduction by p53 class mediator 1.187E-5 1.653E-4 1.145E-3 6.776E-3 4 263
42 GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity 1.996E-5 2.713E-4 1.879E-3 1.139E-2 3 94
43 GO:1904029 regulation of cyclin-dependent protein kinase activity 2.331E-5 3.096E-4 2.144E-3 1.331E-2 3 99
44 GO:0036294 cellular response to decreased oxygen levels 8.060E-5 1.046E-3 7.244E-3 4.602E-2 3 150
45 GO:0071453 cellular response to oxygen levels 9.405E-5 1.193E-3 8.265E-3
5.370E-2
 3 158
46 GO:0006338 chromatin remodeling 1.050E-4 1.304E-3 9.030E-3
5.998E-2
 3 164
47 GO:0000083 regulation of transcription involved in G1/S transition of mitotic cell cycle 1.104E-4 1.342E-3 9.292E-3
6.306E-2
 2 27
48 GO:0000086 G2/M transition of mitotic cell cycle 1.807E-4 2.150E-3 1.489E-2
1.032E-1
 3 197
49 GO:0044839 cell cycle G2/M phase transition 2.032E-4 2.368E-3 1.640E-2
1.160E-1
 3 205
50 GO:1903050 regulation of proteolysis involved in cellular protein catabolic process 4.416E-4 5.043E-3 3.492E-2
2.521E-1
 3 267
Show 45 more annotations

3: GO: Cellular Component [Display Chart] 11 input genes in category / 33 annotations before applied cutoff / 19061 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0000785 chromatin 1.118E-7 3.689E-6 1.508E-5 3.689E-6 6 487
2 GO:0035189 Rb-E2F complex 1.816E-6 2.996E-5 1.225E-4 5.991E-5 2 4
3 GO:0005667 transcription factor complex 4.052E-5 4.457E-4 1.822E-3 1.337E-3 4 368
4 GO:0070603 SWI/SNF superfamily-type complex 7.995E-4 6.065E-3 2.480E-2 2.638E-2 2 74
5 GO:0016604 nuclear body 1.017E-3 6.065E-3 2.480E-2 3.356E-2 3 364
6 GO:0000792 heterochromatin 1.103E-3 6.065E-3 2.480E-2 3.639E-2 2 87
7 GO:0016605 PML body 1.425E-3 6.602E-3 2.699E-2 4.701E-2 2 99
8 GO:0090575 RNA polymerase II transcription factor complex 1.600E-3 6.602E-3 2.699E-2
5.281E-2
 2 105
9 GO:0035985 senescence-associated heterochromatin focus 2.307E-3 8.457E-3 3.458E-2
7.612E-2
 1 4
10 GO:0044798 nuclear transcription factor complex 2.588E-3 8.541E-3 3.492E-2
8.541E-2
 2 134
11 GO:0001652 granular component 3.458E-3 9.510E-3 3.888E-2
1.141E-1
 1 6
12 GO:0008024 cyclin/CDK positive transcription elongation factor complex 3.458E-3 9.510E-3 3.888E-2
1.141E-1
 1 6
13 GO:0019908 nuclear cyclin-dependent protein kinase holoenzyme complex 8.625E-3 2.033E-2
8.312E-2
2.846E-1
 1 15
14 GO:0016514 SWI/SNF complex 8.625E-3 2.033E-2
8.312E-2
2.846E-1
 1 15
15 GO:0001741 XY body 9.770E-3 2.149E-2
8.788E-2
3.224E-1
 1 17
16 GO:0005819 spindle 1.300E-2 2.562E-2
1.047E-1
4.290E-1
 2 308
17 GO:0032806 carboxy-terminal domain protein kinase complex 1.320E-2 2.562E-2
1.047E-1
4.355E-1
 1 23
18 GO:0000307 cyclin-dependent protein kinase holoenzyme complex 1.832E-2 3.181E-2
1.301E-1
6.045E-1
 1 32
19 GO:0000803 sex chromosome 1.832E-2 3.181E-2
1.301E-1
6.045E-1
 1 32
20 GO:0008023 transcription elongation factor complex 2.849E-2 4.700E-2
1.922E-1
9.401E-1
 1 50
Show 15 more annotations

4: Human Phenotype [Display Chart] 2 input genes in category / 546 annotations before applied cutoff / 4707 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 HP:0007716 Uveal melanoma 8.216E-6 4.486E-3 3.087E-2 4.486E-3 2 14
2 HP:0005526 Lymphoid leukemia 1.937E-4 1.749E-2
1.203E-1
1.057E-1
 2 66
3 HP:0100707 Abnormality of the astrocytes 3.073E-4 1.749E-2
1.203E-1
1.678E-1
 2 83
4 HP:0009592 Astrocytoma 3.073E-4 1.749E-2
1.203E-1
1.678E-1
 2 83
5 HP:0002671 Basal cell carcinoma 3.378E-4 1.749E-2
1.203E-1
1.844E-1
 2 87
6 HP:0100787 Prostate neoplasm 3.456E-4 1.749E-2
1.203E-1
1.887E-1
 2 88
7 HP:0003003 Colon cancer 3.456E-4 1.749E-2
1.203E-1
1.887E-1
 2 88
8 HP:0012142 Pancreatic squamous cell carcinoma 4.249E-4 1.749E-2
1.203E-1
2.320E-1
 1 1
9 HP:0011497 Iris neovascularization 4.249E-4 1.749E-2
1.203E-1
2.320E-1
 1 1
10 HP:0100273 Neoplasm of the colon 4.291E-4 1.749E-2
1.203E-1
2.343E-1
 2 98
11 HP:0009733 Glioma 5.025E-4 1.749E-2
1.203E-1
2.743E-1
 2 106
12 HP:0000024 Prostatitis 5.314E-4 1.749E-2
1.203E-1
2.902E-1
 2 109
13 HP:0002902 Hyponatremia 5.413E-4 1.749E-2
1.203E-1
2.955E-1
 2 110
14 HP:0002667 Nephroblastoma 5.816E-4 1.749E-2
1.203E-1
3.175E-1
 2 114
15 HP:0011794 Embryonal renal neoplasm 6.022E-4 1.749E-2
1.203E-1
3.288E-1
 2 116
16 HP:0010931 Abnormality of sodium homeostasis 6.774E-4 1.749E-2
1.203E-1
3.699E-1
 2 123
17 HP:0006775 Multiple myeloma 6.997E-4 1.749E-2
1.203E-1
3.821E-1
 2 125
18 HP:0001067 Neurofibromas 6.997E-4 1.749E-2
1.203E-1
3.821E-1
 2 125
19 HP:0100544 Neoplasm of the heart 7.110E-4 1.749E-2
1.203E-1
3.882E-1
 2 126
20 HP:0100834 Neoplasm of the large intestine 7.224E-4 1.749E-2
1.203E-1
3.944E-1
 2 127
21 HP:0001402 Hepatocellular carcinoma 7.688E-4 1.749E-2
1.203E-1
4.198E-1
 2 131
22 HP:0000554 Uveitis 7.688E-4 1.749E-2
1.203E-1
4.198E-1
 2 131
23 HP:0008775 Abnormality of the prostate 7.688E-4 1.749E-2
1.203E-1
4.198E-1
 2 131
24 HP:0002894 Neoplasm of the pancreas 7.688E-4 1.749E-2
1.203E-1
4.198E-1
 2 131
25 HP:0007862 Retinal calcification 8.497E-4 1.777E-2
1.222E-1
4.639E-1
 1 2
26 HP:0012182 Oropharyngeal squamous cell carcinoma 8.497E-4 1.777E-2
1.222E-1
4.639E-1
 1 2
27 HP:0006721 Acute lymphoblastic leukemia 8.785E-4 1.777E-2
1.222E-1
4.797E-1
 2 140
28 HP:0004808 Acute myeloid leukemia 1.148E-3 2.000E-2
1.376E-1
6.271E-1
 2 160
29 HP:0100526 Neoplasm of the lung 1.148E-3 2.000E-2
1.376E-1
6.271E-1
 2 160
30 HP:0100606 Neoplasm of the respiratory system 1.222E-3 2.000E-2
1.376E-1
6.670E-1
 2 165
31 HP:0003155 Elevated alkaline phosphatase 1.222E-3 2.000E-2
1.376E-1
6.670E-1
 2 165
32 HP:0002653 Bone pain 1.267E-3 2.000E-2
1.376E-1
6.915E-1
 2 168
33 HP:0007905 Abnormal iris vasculature 1.274E-3 2.000E-2
1.376E-1
6.958E-1
 1 3
34 HP:0010930 Abnormality of monovalent inorganic cation homeostasis 1.282E-3 2.000E-2
1.376E-1
6.998E-1
 2 169
35 HP:0004379 Abnormality of alkaline phosphatase activity 1.282E-3 2.000E-2
1.376E-1
6.998E-1
 2 169
36 HP:0002861 Melanoma 1.359E-3 2.005E-2
1.380E-1
7.420E-1
 2 174
37 HP:0002896 Neoplasm of the liver 1.359E-3 2.005E-2
1.380E-1
7.420E-1
 2 174
38 HP:0100750 Atelectasis 1.504E-3 2.061E-2
1.418E-1
8.210E-1
 2 183
39 HP:0009919 Retinoblastoma 1.638E-3 2.061E-2
1.418E-1
8.945E-1
 2 191
40 HP:0012777 Retinal neoplasm 1.638E-3 2.061E-2
1.418E-1
8.945E-1
 2 191
41 HP:0001062 Atypical nevus 1.699E-3 2.061E-2
1.418E-1
9.277E-1
 1 4
42 HP:0001074 Atypical nevi in non-sun exposed areas 1.699E-3 2.061E-2
1.418E-1
9.277E-1
 1 4
43 HP:0001541 Ascites 1.743E-3 2.061E-2
1.418E-1
9.517E-1
 2 197
44 HP:0030067 Peripheral primitive neuroectodermal neoplasm 1.779E-3 2.061E-2
1.418E-1
9.712E-1
 2 199
45 HP:0003006 Neuroblastoma 1.779E-3 2.061E-2
1.418E-1
9.712E-1
 2 199
46 HP:0002097 Emphysema 1.797E-3 2.061E-2
1.418E-1
9.810E-1
 2 200
47 HP:0030065 Primitive neuroectodermal tumor 1.815E-3 2.061E-2
1.418E-1
9.909E-1
 2 201
48 HP:0004376 Neuroblastic tumors 1.888E-3 2.061E-2
1.418E-1
1.000E0
 2 205
49 HP:0010785 Gonadal neoplasm 1.888E-3 2.061E-2
1.418E-1
1.000E0
 2 205
50 HP:0012379 Abnormal enzyme/coenzyme activity 1.925E-3 2.061E-2
1.418E-1
1.000E0
 2 207
Show 45 more annotations

5: Mouse Phenotype [Display Chart] 11 input genes in category / 1029 annotations before applied cutoff / 10355 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 MP:0010295 increased eye tumor incidence 2.408E-11 2.478E-8 1.862E-7 2.478E-8 4 7
2 MP:0008019 increased liver tumor incidence 2.296E-9 8.960E-7 6.733E-6 2.362E-6 6 139
3 MP:0010297 increased hepatobiliary system tumor incidence 2.612E-9 8.960E-7 6.733E-6 2.688E-6 6 142
4 MP:0006310 increased retinoblastoma incidence 3.565E-9 9.172E-7 6.892E-6 3.669E-6 3 4
5 MP:0010303 increased retina tumor incidence 8.909E-9 1.629E-6 1.224E-5 9.167E-6 3 5
6 MP:0002027 increased lung adenocarcinoma incidence 9.498E-9 1.629E-6 1.224E-5 9.774E-6 5 78
7 MP:0008716 increased lung non-small cell carcinoma incidence 1.471E-8 2.162E-6 1.625E-5 1.513E-5 5 85
8 MP:0001222 epidermal hyperplasia 4.498E-8 5.125E-6 3.851E-5 4.628E-5 5 106
9 MP:0008714 increased lung carcinoma incidence 4.716E-8 5.125E-6 3.851E-5 4.853E-5 5 107
10 MP:0004385 interparietal bone hypoplasia 4.980E-8 5.125E-6 3.851E-5 5.125E-5 3 8
11 MP:0008021 increased blastoma incidence 7.558E-8 7.070E-6 5.312E-5 7.777E-5 4 42
12 MP:0006309 decreased retinal ganglion cell number 9.156E-8 7.851E-6 5.900E-5 9.422E-5 4 44
13 MP:0005241 abnormal retinal ganglion layer morphology 1.162E-7 9.196E-6 6.910E-5 1.195E-4 5 128
14 MP:0005240 abnormal amacrine cell morphology 1.965E-7 1.445E-5 1.085E-4 2.022E-4 4 53
15 MP:0006073 abnormal retinal bipolar cell morphology 2.287E-7 1.450E-5 1.089E-4 2.353E-4 4 55
16 MP:0010298 increased respiratory system tumor incidence 2.486E-7 1.450E-5 1.089E-4 2.558E-4 5 149
17 MP:0008014 increased lung tumor incidence 2.486E-7 1.450E-5 1.089E-4 2.558E-4 5 149
18 MP:0009550 increased urinary bladder carcinoma incidence 2.536E-7 1.450E-5 1.089E-4 2.610E-4 3 13
19 MP:0002038 increased carcinoma incidence 3.187E-7 1.726E-5 1.297E-4 3.280E-4 6 317
20 MP:0009308 increased adenocarcinoma incidence 6.200E-7 3.190E-5 2.397E-4 6.380E-4 5 179
21 MP:0010281 increased nervous system tumor incidence 7.635E-7 3.606E-5 2.710E-4 7.857E-4 4 74
22 MP:0003721 increased tumor growth/size 8.061E-7 3.606E-5 2.710E-4 8.295E-4 4 75
23 MP:0001239 abnormal epidermis stratum granulosum morphology 8.061E-7 3.606E-5 2.710E-4 8.295E-4 4 75
24 MP:0003111 abnormal cell nucleus morphology 9.010E-7 3.863E-5 2.903E-4 9.271E-4 5 193
25 MP:0008218 delayed emergence of vibrissae 1.026E-6 4.223E-5 3.173E-4 1.056E-3 2 2
26 MP:0002018 increased malignant tumor incidence 1.131E-6 4.474E-5 3.362E-4 1.164E-3 6 393
27 MP:0005161 hematuria 1.174E-6 4.474E-5 3.362E-4 1.208E-3 3 21
28 MP:0001270 distended abdomen 2.089E-6 7.675E-5 5.767E-4 2.149E-3 4 95
29 MP:0008056 abnormal retinal ganglion cell morphology 2.566E-6 9.103E-5 6.840E-4 2.640E-3 4 100
30 MP:0010290 increased muscle tumor incidence 2.880E-6 9.878E-5 7.422E-4 2.963E-3 3 28
31 MP:0004384 small interparietal bone 3.565E-6 1.146E-4 8.613E-4 3.668E-3 3 30
32 MP:0010289 increased urinary system tumor incidence 3.565E-6 1.146E-4 8.613E-4 3.668E-3 3 30
33 MP:0004025 polyploidy 3.944E-6 1.230E-4 9.242E-4 4.059E-3 3 31
34 MP:0006096 absent retinal bipolar cells 6.149E-6 1.861E-4 1.398E-3 6.327E-3 2 4
35 MP:0001242 hyperkeratosis 6.457E-6 1.898E-4 1.426E-3 6.644E-3 4 126
36 MP:0010320 increased pituitary gland tumor incidence 6.795E-6 1.942E-4 1.459E-3 6.992E-3 3 37
37 MP:0010639 altered tumor pathology 7.776E-6 2.162E-4 1.625E-3 8.001E-3 5 299
38 MP:0008715 increased lung small cell carcinoma incidence 1.024E-5 2.702E-4 2.031E-3 1.054E-2 2 5
39 MP:0008068 absent retinal ganglion cell 1.024E-5 2.702E-4 2.031E-3 1.054E-2 2 5
40 MP:0002032 increased sarcoma incidence 1.290E-5 3.252E-4 2.443E-3 1.327E-2 4 150
41 MP:0003077 abnormal cell cycle 1.296E-5 3.252E-4 2.443E-3 1.333E-2 5 332
42 MP:0011703 increased fibroblast proliferation 1.600E-5 3.920E-4 2.945E-3 1.646E-2 3 49
43 MP:0001286 abnormal eye development 1.675E-5 3.978E-4 2.989E-3 1.723E-2 5 350
44 MP:0003734 abnormal retinal inner plexiform layer morphology 1.701E-5 3.978E-4 2.989E-3 1.750E-2 3 50
45 MP:0006069 abnormal retinal neuronal layer morphology 2.026E-5 4.421E-4 3.322E-3 2.084E-2 5 364
46 MP:0001240 abnormal epidermis stratum corneum morphology 2.066E-5 4.421E-4 3.322E-3 2.126E-2 4 169
47 MP:0001216 abnormal epidermal layer morphology 2.080E-5 4.421E-4 3.322E-3 2.140E-2 5 366
48 MP:0008300 enlarged adrenal medulla 2.148E-5 4.421E-4 3.322E-3 2.211E-2 2 7
49 MP:0005299 abnormal eye posterior chamber morphology 2.148E-5 4.421E-4 3.322E-3 2.211E-2 2 7
50 MP:0008301 adrenal medulla hyperplasia 2.148E-5 4.421E-4 3.322E-3 2.211E-2 2 7
Show 45 more annotations

6: Domain [Display Chart] 11 input genes in category / 67 annotations before applied cutoff / 18735 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 SM01369 Rb C SMART 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
2 IPR024599 RB N InterPro 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
3 PF01858 RB A Pfam 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
4 IPR028309 RB fam InterPro 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
5 PF01857 RB B Pfam 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
6 IPR002720 RB A InterPro 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
7 SM01367 DUF3452 SMART 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
8 PF11934 DUF3452 Pfam 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
9 SM01368 RB A SMART 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
10 IPR002719 RB B InterPro 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
11 IPR015030 RB C InterPro 1.506E-10 9.171E-10 4.392E-9 1.009E-8 3 3
12 SM00385 CYCLIN SMART 4.699E-9 2.623E-8 1.256E-7 3.148E-7 4 38
13 1.10.472.10 - Gene3D 5.814E-9 2.996E-8 1.435E-7 3.895E-7 4 40
14 IPR013763 Cyclin-like InterPro 7.844E-9 3.754E-8 1.798E-7 5.255E-7 4 43
15 PF08934 Rb C Pfam 3.134E-7 1.400E-6 6.705E-6 2.100E-5 2 2
16 IPR005012 Daxx InterPro 5.871E-4 1.574E-3 7.536E-3 3.934E-2 1 1
17 IPR028310 RBL1 InterPro 5.871E-4 1.574E-3 7.536E-3 3.934E-2 1 1
18 IPR033057 RB1 InterPro 5.871E-4 1.574E-3 7.536E-3 3.934E-2 1 1
19 IPR020658 Ser/Thr kinase Plk3 InterPro 5.871E-4 1.574E-3 7.536E-3 3.934E-2 1 1
20 IPR028308 RB2 InterPro 5.871E-4 1.574E-3 7.536E-3 3.934E-2 1 1
21 IPR010868 Tumor suppres ARF InterPro 5.871E-4 1.574E-3 7.536E-3 3.934E-2 1 1
22 PF07392 P19Arf N Pfam 5.871E-4 1.574E-3 7.536E-3 3.934E-2 1 1
23 PF03344 Daxx Pfam 5.871E-4 1.574E-3 7.536E-3 3.934E-2 1 1
24 IPR031333 Daxx N InterPro 5.871E-4 1.574E-3 7.536E-3 3.934E-2 1 1
25 IPR028860 CCNG1 InterPro 5.871E-4 1.574E-3 7.536E-3 3.934E-2 1 1
26 IPR000406 Rho GDI InterPro 1.760E-3 3.932E-3 1.883E-2
1.180E-1
 1 3
27 PF02115 Rho GDI Pfam 1.760E-3 3.932E-3 1.883E-2
1.180E-1
 1 3
28 2.70.50.30 - Gene3D 1.760E-3 3.932E-3 1.883E-2
1.180E-1
 1 3
29 IPR033695 POLO box 2 InterPro 1.760E-3 3.932E-3 1.883E-2
1.180E-1
 1 3
30 IPR024792 RhoGDI domain InterPro 1.760E-3 3.932E-3 1.883E-2
1.180E-1
 1 3
31 PS50078 POLO BOX PROSITE 2.347E-3 4.624E-3 2.215E-2
1.572E-1
 1 4
32 3.30.1120.30 - Gene3D 2.347E-3 4.624E-3 2.215E-2
1.572E-1
 1 4
33 IPR033701 POLO box 1 InterPro 2.347E-3 4.624E-3 2.215E-2
1.572E-1
 1 4
34 PF00659 POLO box Pfam 2.347E-3 4.624E-3 2.215E-2
1.572E-1
 1 4
35 IPR000959 POLO box dom InterPro 2.933E-3 5.171E-3 2.476E-2
1.965E-1
 1 5
36 PF06031 SERTA Pfam 2.933E-3 5.171E-3 2.476E-2
1.965E-1
 1 5
37 PS51053 SERTA PROSITE 2.933E-3 5.171E-3 2.476E-2
1.965E-1
 1 5
38 IPR009263 SERTA dom InterPro 2.933E-3 5.171E-3 2.476E-2
1.965E-1
 1 5
39 PF16421 E2F CC-MB Pfam 3.518E-3 5.893E-3 2.822E-2
2.357E-1
 1 6
40 IPR032198 E2F CC-MB InterPro 3.518E-3 5.893E-3 2.822E-2
2.357E-1
 1 6
41 IPR015633 E2F InterPro 4.688E-3 7.661E-3 3.669E-2
3.141E-1
 1 8
42 SM01372 E2F TDP SMART 6.441E-3 9.808E-3 4.698E-2
4.316E-1
 1 11
43 PF02319 E2F TDP Pfam 6.441E-3 9.808E-3 4.698E-2
4.316E-1
 1 11
44 IPR003316 E2F WHTH DNA-bd dom InterPro 6.441E-3 9.808E-3 4.698E-2
4.316E-1
 1 11
45 PS00292 CYCLINS PROSITE 1.632E-2 2.430E-2
1.164E-1
1.000E0
 1 28
46 IPR006671 Cyclin N InterPro 1.921E-2 2.739E-2
1.312E-1
1.000E0
 1 33
47 PF00134 Cyclin N Pfam 1.921E-2 2.739E-2
1.312E-1
1.000E0
 1 33
Show 42 more annotations

7: Pathway [Display Chart] 10 input genes in category / 149 annotations before applied cutoff / 12450 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 1269766 G1 Phase BioSystems: REACTOME 5.759E-11 4.291E-9 2.396E-8 8.581E-9 5 39
2 1269767 Cyclin D associated events in G1 BioSystems: REACTOME 5.759E-11 4.291E-9 2.396E-8 8.581E-9 5 39
3 M17770 Cyclins and Cell Cycle Regulation MSigDB C2 BIOCARTA (v6.0) 1.845E-9 8.637E-8 4.823E-7 2.749E-7 4 23
4 1269654 Transcriptional Regulation by TP53 BioSystems: REACTOME 2.319E-9 8.637E-8 4.823E-7 3.455E-7 7 374
5 83054 Cell cycle BioSystems: KEGG 2.189E-8 6.522E-7 3.642E-6 3.261E-6 5 124
6 1383071 TP53 Regulates Transcription of Cell Cycle Genes BioSystems: REACTOME 4.370E-8 1.024E-6 5.716E-6 6.512E-6 4 49
7 1269764 Mitotic G1-G1/S phases BioSystems: REACTOME 4.809E-8 1.024E-6 5.716E-6 7.165E-6 5 145
8 137934 E2F transcription factor network BioSystems: Pathway Interaction Database 2.224E-7 4.143E-6 2.313E-5 3.314E-5 4 73
9 M11358 Tumor Suppressor Arf Inhibits Ribosomal Biogenesis MSigDB C2 BIOCARTA (v6.0) 2.523E-7 4.177E-6 2.332E-5 3.759E-5 3 17
10 M14449 METS affect on Macrophage Differentiation MSigDB C2 BIOCARTA (v6.0) 3.026E-7 4.509E-6 2.518E-5 4.509E-5 3 18
11 1269765 G0 and Early G1 BioSystems: REACTOME 8.504E-7 1.152E-5 6.433E-5 1.267E-4 3 25
12 M648 Cell Cycle: G1/S Check Point MSigDB C2 BIOCARTA (v6.0) 1.210E-6 1.502E-5 8.388E-5 1.803E-4 3 28
13 M9503 FAS signaling pathway ( CD95 ) MSigDB C2 BIOCARTA (v6.0) 1.498E-6 1.717E-5 9.588E-5 2.232E-4 3 30
14 1383079 Regulation of TP53 Degradation BioSystems: REACTOME 2.410E-6 2.565E-5 1.432E-4 3.591E-4 3 35
15 1383077 Regulation of TP53 Expression and Degradation BioSystems: REACTOME 2.628E-6 2.610E-5 1.458E-4 3.915E-4 3 36
16 83115 Bladder cancer BioSystems: KEGG 3.915E-6 3.646E-5 2.036E-4 5.833E-4 3 41
17 P04398 p53 pathway feedback loops 2 PantherDB 5.202E-6 4.518E-5 2.523E-4 7.752E-4 3 45
18 1383076 Regulation of TP53 Activity BioSystems: REACTOME 5.458E-6 4.518E-5 2.523E-4 8.132E-4 4 162
19 83119 Non-small cell lung cancer BioSystems: KEGG 1.125E-5 8.382E-5 4.681E-4 1.676E-3 3 58
20 M13968 HIV-I Nef: negative effector of Fas and TNF MSigDB C2 BIOCARTA (v6.0) 1.125E-5 8.382E-5 4.681E-4 1.676E-3 3 58
21 138067 p53 pathway BioSystems: Pathway Interaction Database 1.185E-5 8.407E-5 4.695E-4 1.765E-3 3 59
22 658418 Viral carcinogenesis BioSystems: KEGG 1.283E-5 8.691E-5 4.854E-4 1.912E-3 4 201
23 83108 Pancreatic cancer BioSystems: KEGG 1.515E-5 9.408E-5 5.254E-4 2.258E-3 3 64
24 83110 Glioma BioSystems: KEGG 1.515E-5 9.408E-5 5.254E-4 2.258E-3 3 64
25 83114 Melanoma BioSystems: KEGG 1.902E-5 1.133E-4 6.329E-4 2.833E-3 3 69
26 83116 Chronic myeloid leukemia BioSystems: KEGG 2.073E-5 1.188E-4 6.633E-4 3.088E-3 3 71
27 M6031 E2F1 Destruction Pathway MSigDB C2 BIOCARTA (v6.0) 2.604E-5 1.437E-4 8.025E-4 3.880E-3 2 10
28 M3686 Expression of cyclins regulates progression through the cell cycle by activating cyclin-dependent kinases. MSigDB C2 BIOCARTA (v6.0) 4.508E-5 2.239E-4 1.250E-3 6.717E-3 2 13
29 M17977 Regulation of p27 Phosphorylation during Cell Cycle Progression MSigDB C2 BIOCARTA (v6.0) 4.508E-5 2.239E-4 1.250E-3 6.717E-3 2 13
30 1269775 Inhibition of replication initiation of damaged DNA by RB1/E2F1 BioSystems: REACTOME 4.508E-5 2.239E-4 1.250E-3 6.717E-3 2 13
31 1404799 Endocrine resistance BioSystems: KEGG 5.127E-5 2.464E-4 1.376E-3 7.639E-3 3 96
32 M1529 Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. MSigDB C2 BIOCARTA (v6.0) 6.063E-5 2.823E-4 1.577E-3 9.034E-3 2 15
33 M14863 p53 Signaling Pathway MSigDB C2 BIOCARTA (v6.0) 6.927E-5 3.127E-4 1.747E-3 1.032E-2 2 16
34 M4891 Regulation of transcriptional activity by PML MSigDB C2 BIOCARTA (v6.0) 7.847E-5 3.439E-4 1.920E-3 1.169E-2 2 17
35 1383073 TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest BioSystems: REACTOME 9.858E-5 4.197E-4 2.344E-3 1.469E-2 2 19
36 137939 Direct p53 effectors BioSystems: Pathway Interaction Database 1.324E-4 5.480E-4 3.060E-3 1.973E-2 3 132
37 M14512 Influence of Ras and Rho proteins on G1 to S Transition MSigDB C2 BIOCARTA (v6.0) 1.868E-4 7.522E-4 4.201E-3 2.783E-2 2 26
38 M3618 TNFR1 Signaling Pathway MSigDB C2 BIOCARTA (v6.0) 2.330E-4 9.138E-4 5.103E-3 3.472E-2 2 29
39 1270427 Oncogene Induced Senescence BioSystems: REACTOME 2.843E-4 1.086E-3 6.067E-3 4.237E-2 2 32
40 1269774 E2F mediated regulation of DNA replication BioSystems: REACTOME 3.213E-4 1.197E-3 6.684E-3 4.788E-2 2 34
41 1270426 Cellular Senescence BioSystems: REACTOME 4.314E-4 1.568E-3 8.755E-3
6.428E-2
 3 197
42 169347 Notch-mediated HES/HEY network BioSystems: Pathway Interaction Database 6.422E-4 2.278E-3 1.272E-2
9.569E-2
 2 48
43 373901 HTLV-I infection BioSystems: KEGG 9.265E-4 3.210E-3 1.793E-2
1.380E-1
 3 256
44 83055 p53 signaling pathway BioSystems: KEGG 1.324E-3 4.483E-3 2.503E-2
1.972E-1
 2 69
45 852705 MicroRNAs in cancer BioSystems: KEGG 1.452E-3 4.807E-3 2.684E-2
2.163E-1
 3 299
46 1269794 Regulation of DNA replication BioSystems: REACTOME 1.731E-3 5.488E-3 3.065E-2
2.579E-1
 2 79
47 P00059 p53 pathway PantherDB 1.731E-3 5.488E-3 3.065E-2
2.579E-1
 2 79
48 83118 Small cell lung cancer BioSystems: KEGG 1.954E-3 6.067E-3 3.388E-2
2.912E-1
 2 84
49 83111 Prostate cancer BioSystems: KEGG 2.095E-3 6.369E-3 3.557E-2
3.121E-1
 2 87
50 1269771 Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes BioSystems: REACTOME 3.209E-3 9.228E-3
5.154E-2
4.782E-1
 1 4
Show 45 more annotations

8: Pubmed [Display Chart] 11 input genes in category / 6395 annotations before applied cutoff / 38193 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 26238783 A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. Pubmed 1.718E-16 1.099E-12 1.026E-11 1.099E-12 5 10
2 19738611 Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Pubmed 3.485E-16 1.114E-12 1.041E-11 2.229E-12 6 39
3 16465443 Retinoblastoma family proteins: insights gained through genetic manipulation of mice. Pubmed 8.773E-16 1.870E-12 1.747E-11 5.610E-12 5 13
4 19864318 Retinoblastoma 1 protein modulates XY germ cell entry into G1/G0 arrest during fetal development in mice. Pubmed 1.056E-14 1.350E-11 1.261E-10 6.752E-11 5 20
5 22810586 Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Pubmed 1.056E-14 1.350E-11 1.261E-10 6.752E-11 5 20
6 12450794 Che-1 affects cell growth by interfering with the recruitment of HDAC1 by Rb. Pubmed 5.582E-14 5.100E-11 4.764E-10 3.570E-10 4 6
7 26639898 Recruitment of Pontin/Reptin by E2f1 amplifies E2f transcriptional response during cancer progression. Pubmed 5.582E-14 5.100E-11 4.764E-10 3.570E-10 4 6
8 12096339 Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Pubmed 1.302E-13 8.329E-11 7.779E-10 8.329E-10 4 7
9 10022926 Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins. Pubmed 1.302E-13 8.329E-11 7.779E-10 8.329E-10 4 7
10 18818403 The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Pubmed 1.302E-13 8.329E-11 7.779E-10 8.329E-10 4 7
11 15664192 Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Pubmed 7.811E-13 4.541E-10 4.241E-9 4.995E-9 4 10
12 15735762 Induction of human metallothionein 1G promoter by VEGF and heavy metals: differential involvement of E2F and metal transcription factors. Pubmed 1.227E-12 6.540E-10 6.109E-9 7.848E-9 4 11
13 25533675 Modelling bladder cancer in mice: opportunities and challenges. Pubmed 1.841E-12 9.054E-10 8.457E-9 1.177E-8 4 12
14 10082561 C/EBPalpha regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice. Pubmed 5.073E-12 2.317E-9 2.165E-8 3.244E-8 4 15
15 22714890 Pattern of expression of p53, its family members, and regulators during early ocular development and in the post-mitotic retina. Pubmed 6.763E-12 2.583E-9 2.413E-8 4.325E-8 4 16
16 15843406 The retinoblastoma gene pathway regulates the postmitotic state of hair cells of the mouse inner ear. Pubmed 1.137E-11 2.583E-9 2.413E-8 7.270E-8 4 18
17 19341623 Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
18 9150384 The retinoblastoma gene family is differentially expressed during embryogenesis. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
19 12627794 Expression of the retinoblastoma family of tumor suppressors during murine embryonic orofacial development. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
20 17597480 Latent membrane protein 1 encoded by Epstein-Barr virus induces telomerase activity via p16INK4A/Rb/E2F1 and JNK signaling pathways. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
21 9508781 A critical temporal requirement for the retinoblastoma protein family during neuronal determination. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
22 11114893 Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
23 9192872 pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
24 27966456 Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
25 24227978 Animal models in retinoblastoma research. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
26 17956737 Differentiated horizontal interneurons clonally expand to form metastatic retinoblastoma in mice. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
27 18940733 Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
28 11114892 Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
29 20100864 Regulation of RB transcription in vivo by RB family members. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
30 18981186 Retinoblastoma protein (pRb), but not p107 or p130, is required for maintenance of enterocyte quiescence and differentiation in small intestine. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
31 19279001 Retinoblastoma/p107/p130 pocket proteins: protein dynamics and interactions with target gene promoters. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
32 22237625 Pocket proteins suppress head and neck cancer. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
33 10630640 The retinoblastoma gene family in differentiation and development. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
34 12379853 A role for the Rb family of proteins in controlling telomere length. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
35 19509021 The retinoblastoma protein and its homolog p130 regulate the G1/S transition in pancreatic beta-cells. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
36 19887614 Retinoblastoma family proteins have distinct functions in pulmonary epithelial cells in vivo critical for suppressing cell growth and tumorigenesis. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
37 9110405 Genes in the RB pathway and their knockout in mice. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
38 22942253 Inactivating all three rb family pocket proteins is insufficient to initiate cervical cancer. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
39 15827088 p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
40 19887370 Unique impact of RB loss on hepatic proliferation: tumorigenic stresses uncover distinct pathways of cell cycle control. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
41 9751770 pRB plays an essential role in cell cycle arrest induced by DNA damage. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
42 12621062 Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
43 19649275 Activation of NF-kB pathway by virus infection requires Rb expression. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
44 8682293 Targeted disruption of p107: functional overlap between p107 and Rb. Pubmed 1.777E-11 2.583E-9 2.413E-8 1.136E-7 3 3
45 14688262 Ras protects Rb family null fibroblasts from cell death: a role for AP-1. Pubmed 7.107E-11 6.402E-9 5.980E-8 4.545E-7 3 4
46 10376528 Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Pubmed 7.107E-11 6.402E-9 5.980E-8 4.545E-7 3 4
47 28550162 Rb family proteins enforce the homeostasis of quiescent hematopoietic stem cells by repressing Socs3 expression. Pubmed 7.107E-11 6.402E-9 5.980E-8 4.545E-7 3 4
48 16258171 The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. Pubmed 7.107E-11 6.402E-9 5.980E-8 4.545E-7 3 4
49 17620057 Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Pubmed 7.107E-11 6.402E-9 5.980E-8 4.545E-7 3 4
50 24086435 High incidence of HPV-associated head and neck cancers in FA deficient mice is associated with E7's induction of DNA damage through its inactivation of pocket proteins. Pubmed 7.107E-11 6.402E-9 5.980E-8 4.545E-7 3 4
Show 45 more annotations

9: Interaction [Display Chart] 11 input genes in category / 826 annotations before applied cutoff / 17703 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 int:MT1G MT1G interactions 5.751E-11 4.750E-8 3.465E-7 4.750E-8 4 13
2 int:TFDP1 TFDP1 interactions 5.040E-10 1.615E-7 1.178E-6 4.163E-7 5 74
3 int:TFDP2 TFDP2 interactions 5.867E-10 1.615E-7 1.178E-6 4.846E-7 4 22
4 int:CDKN2A CDKN2A interactions 1.682E-9 3.474E-7 2.534E-6 1.389E-6 6 224
5 int:CCNE1 CCNE1 interactions 2.716E-9 4.488E-7 3.273E-6 2.244E-6 5 103
6 int:RBBP9 RBBP9 interactions 3.566E-9 4.909E-7 3.581E-6 2.945E-6 3 6
7 int:E2F2 E2F2 interactions 1.081E-8 1.276E-6 9.307E-6 8.931E-6 4 44
8 int:KMT5B KMT5B interactions 2.137E-8 1.974E-6 1.440E-5 1.765E-5 3 10
9 int:CCNA1 CCNA1 interactions 2.151E-8 1.974E-6 1.440E-5 1.777E-5 4 52
10 int:E2F1 E2F1 interactions 2.505E-8 2.069E-6 1.509E-5 2.069E-5 5 160
11 int:DYRK1B DYRK1B interactions 4.716E-8 3.502E-6 2.554E-5 3.895E-5 4 63
12 int:CREG1 CREG1 interactions 5.087E-8 3.502E-6 2.554E-5 4.202E-5 3 13
13 int:KMT5C KMT5C interactions 8.087E-8 5.139E-6 3.748E-5 6.680E-5 3 15
14 int:CDK4 CDK4 interactions 1.204E-7 7.102E-6 5.181E-5 9.943E-5 5 219
15 int:RBL1 RBL1 interactions 1.592E-7 8.766E-6 6.394E-5 1.315E-4 4 85
16 int:MDM2 MDM2 interactions 1.791E-7 9.246E-6 6.744E-5 1.479E-4 6 490
17 int:BRF1 BRF1 interactions 3.139E-7 1.525E-5 1.113E-4 2.593E-4 3 23
18 int:SMARCA4 SMARCA4 interactions 3.536E-7 1.623E-5 1.184E-4 2.921E-4 5 272
19 int:LIN54 LIN54 interactions 4.604E-7 2.002E-5 1.460E-4 3.803E-4 3 26
20 int:DGKZ DGKZ interactions 6.464E-7 2.597E-5 1.895E-4 5.339E-4 3 29
21 int:E2F4 E2F4 interactions 6.603E-7 2.597E-5 1.895E-4 5.454E-4 4 121
22 int:CCND1 CCND1 interactions 7.052E-7 2.648E-5 1.931E-4 5.825E-4 4 123
23 int:CCNA2 CCNA2 interactions 7.767E-7 2.735E-5 1.995E-4 6.416E-4 4 126
24 int:LIN9 LIN9 interactions 7.946E-7 2.735E-5 1.995E-4 6.564E-4 3 31
25 int:LIN37 LIN37 interactions 8.766E-7 2.896E-5 2.113E-4 7.240E-4 3 32
26 int:CCND2 CCND2 interactions 1.253E-6 3.982E-5 2.905E-4 1.035E-3 4 142
27 int:PHB PHB interactions 2.121E-6 6.413E-5 4.678E-4 1.752E-3 4 162
28 int:CDK6 CDK6 interactions 2.174E-6 6.413E-5 4.678E-4 1.796E-3 4 163
29 int:FZR1 FZR1 interactions 2.951E-6 8.404E-5 6.130E-4 2.437E-3 4 176
30 int:BRD2 BRD2 interactions 3.443E-6 9.479E-5 6.914E-4 2.844E-3 3 50
31 int:SUV39H1 SUV39H1 interactions 3.676E-6 9.794E-5 7.144E-4 3.036E-3 4 186
32 int:CENPF CENPF interactions 4.111E-6 1.061E-4 7.740E-4 3.395E-3 3 53
33 int:KAT2B KAT2B interactions 5.304E-6 1.327E-4 9.683E-4 4.381E-3 4 204
34 int:MYBL2 MYBL2 interactions 6.298E-6 1.530E-4 1.116E-3 5.202E-3 3 61
35 int:BIRC5 BIRC5 interactions 9.144E-6 2.132E-4 1.555E-3 7.553E-3 3 69
36 int:RBBP8 RBBP8 interactions 9.550E-6 2.132E-4 1.555E-3 7.888E-3 3 70
37 int:UXT UXT interactions 9.550E-6 2.132E-4 1.555E-3 7.888E-3 3 70
38 int:SP1 SP1 interactions 1.426E-5 2.849E-4 2.078E-3 1.178E-2 4 262
39 int:AATF AATF interactions 1.429E-5 2.849E-4 2.078E-3 1.180E-2 3 80
40 int:RBL2 RBL2 interactions 1.429E-5 2.849E-4 2.078E-3 1.180E-2 3 80
41 int:PML PML interactions 1.469E-5 2.849E-4 2.078E-3 1.214E-2 4 264
42 int:CDC6 CDC6 interactions 1.483E-5 2.849E-4 2.078E-3 1.225E-2 3 81
43 int:E4F1 E4F1 interactions 1.483E-5 2.849E-4 2.078E-3 1.225E-2 3 81
44 int:RB1 RB1 interactions 1.536E-5 2.884E-4 2.103E-3 1.269E-2 4 267
45 int:TAF1 TAF1 interactions 1.714E-5 3.147E-4 2.295E-3 1.416E-2 3 85
46 int:ID2 ID2 interactions 1.903E-5 3.274E-4 2.388E-3 1.572E-2 3 88
47 int:DYRK1A DYRK1A interactions 1.903E-5 3.274E-4 2.388E-3 1.572E-2 3 88
48 int:MDM4 MDM4 interactions 1.903E-5 3.274E-4 2.388E-3 1.572E-2 3 88
49 int:C3orf62 C3orf62 interactions 2.309E-5 3.832E-4 2.795E-3 1.907E-2 2 12
50 int:IRF3 IRF3 interactions 2.320E-5 3.832E-4 2.795E-3 1.916E-2 3 94
Show 45 more annotations

10: Cytoband [Display Chart] 11 input genes in category / 10 annotations before applied cutoff / 34661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 20q11.2 20q11.2 3.200E-5 3.200E-4 9.373E-4 3.200E-4 2 27
2 5q32-q34 5q32-q34 3.174E-4 1.587E-3 4.648E-3 3.174E-3 1 1
3 19q13.1-q13.2 19q13.1-q13.2 2.853E-3 9.510E-3 2.785E-2 2.853E-2 1 9
4 13q14.2 13q14.2 8.852E-3 1.444E-2 4.230E-2
8.852E-2
 1 28
5 16q12.2 16q12.2 8.852E-3 1.444E-2 4.230E-2
8.852E-2
 1 28
6 9p21 9p21 9.481E-3 1.444E-2 4.230E-2
9.481E-2
 1 30
7 12p12.3 12p12.3 1.011E-2 1.444E-2 4.230E-2
1.011E-1
 1 32
8 1p34.1 1p34.1 1.794E-2 2.243E-2
6.570E-2
1.794E-1
 1 57
Show 3 more annotations

11: Transcription Factor Binding Site [Display Chart] 10 input genes in category / 93 annotations before applied cutoff / 9770 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 V$E2F Q6 01 V$E2F Q6 01 7.154E-4 3.709E-2
1.897E-1
6.653E-2
 3 184
2 V$E2F 03 V$E2F 03 7.976E-4 3.709E-2
1.897E-1
7.418E-2
 3 191

12: Gene Family [Display Chart] 5 input genes in category / 4 annotations before applied cutoff / 18194 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 542 Endogenous ligands genenames.org 1.647E-3 4.394E-3 9.153E-3 6.586E-3 2 237
2 982 E2F transcription factors genenames.org 2.197E-3 4.394E-3 9.153E-3 8.787E-3 1 8
3 473 Cyclins genenames.org 7.945E-3 1.059E-2 2.207E-2 3.178E-2 1 29
4 870 Minor histocompatibility antigens|FERM domain containing genenames.org 1.394E-2 1.394E-2 2.904E-2
5.576E-2
 1 51

13: Coexpression [Display Chart] 11 input genes in category / 1679 annotations before applied cutoff / 23137 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 M3278 Genes down-regulated in SaOS-2 cells (osteosarcoma) upon knockdown of YY1 [GeneID=7528] by RNAi. MSigDB C2: CGP Curated Gene Sets (v6.0) 7.561E-8 1.259E-4 1.007E-3 1.270E-4 4 92
2 18339860-Table1 Human Bone deNigris08 118genes GeneSigDB 1.499E-7 1.259E-4 1.007E-3 2.517E-4 4 109
3 M1982 Genes down-regulated in CD4+ [GeneID=920] T lymphocytes transduced with FOXP3 [GeneID=50943]. MSigDB C2: CGP Curated Gene Sets (v6.0) 9.085E-7 5.084E-4 4.069E-3 1.525E-3 3 42
4 M5939 Genes involved in p53 pathways and networks. MSigDB H: Hallmark Gene Sets (v6.0) 1.705E-6 5.173E-4 4.140E-3 2.863E-3 4 200
5 20103679-ST3-D Human Breast Wood10 71genes FoldChange>2 GeneSigDB 1.849E-6 5.173E-4 4.140E-3 3.104E-3 3 53
6 20103679-ST3-A Human Breast Wood10 71genes CellCyle GeneSigDB 1.849E-6 5.173E-4 4.140E-3 3.104E-3 3 53
7 12925741-Figure9 Human Lymphoma Jenner03 92genes GeneSigDB 3.278E-6 7.863E-4 6.293E-3 5.504E-3 3 64
8 M2208 Potential targets of MIR302A [GeneID=407028]. MSigDB C2: CGP Curated Gene Sets (v6.0) 5.736E-6 1.204E-3 9.636E-3 9.631E-3 3 77
9 18234966-Table2 Mouse Ovarian Wang07 85genes GeneSigDB 7.194E-6 1.342E-3 1.074E-2 1.208E-2 3 83
10 15705876-TableS6 Human Leukemia Passioura05 105genes GeneSigDB 1.186E-5 1.982E-3 1.587E-2 1.992E-2 3 98
11 M15356 Genes constituting the LIT-Int network of proteins interacting with breast cancer reference proteins BRCA1, BRCA2, ATM, and CHEK2 [GeneID=672;675;472;11200]; the interactions were manually curated from the literature. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.299E-5 1.982E-3 1.587E-2 2.181E-2 3 101
12 21205295-TableS2 Mouse Viral Buonomo11 116genes GeneSigDB 1.459E-5 2.042E-3 1.634E-2 2.450E-2 3 105
13 M1160 Non-histone proteins that are acetylated. MSigDB C2: CGP Curated Gene Sets (v6.0) 2.150E-5 2.579E-3 2.064E-2 3.611E-2 2 15
14 M2476 Genes up-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3, rested on days 4 and 5, and then restimulated on day 6 for 1 h before lysis (priming model). MSigDB C2: CGP Curated Gene Sets (v6.0) 2.150E-5 2.579E-3 2.064E-2 3.611E-2 2 15
15 17638873-Table1a Human StemCell Singer07 25genes GeneSigDB 2.784E-5 3.116E-3 2.494E-2 4.674E-2 2 17
16 19749795-Table2 Human Leukemia Ueno09 26genes GeneSigDB 3.131E-5 3.286E-3 2.630E-2
5.257E-2
 2 18
17 11573962-Table3 Human Viral Sun01 27genes Cell Cycle-Related GeneSigDB 4.722E-5 4.664E-3 3.733E-2
7.929E-2
 2 22
18 M2995 Genes up-regulated in B lymphocytes stimulated by anti-IgM: ZFX [GeneID=7543] knockout (2h) versus wildtype (12h). MSigDB C7: Immunologic Signatures (v6.0) 5.238E-5 4.886E-3 3.910E-2
8.794E-2
 3 161
19 M7970 Genes down-regulated in BJAB cells (B-lymphoma) after glucose [PubChem=206] deprivation. MSigDB C2: CGP Curated Gene Sets (v6.0) 5.945E-5 5.065E-3 4.054E-2
9.981E-2
 3 168
20 19695104-AF1-4 Human Breast Lin09 28genes GeneSigDB 6.128E-5 5.065E-3 4.054E-2
1.029E-1
 2 25
21 M16488 The lung adenocarcinoma TSP (tumor sequencing project) genes that were found significantly mutated by at least one method. MSigDB C2: CGP Curated Gene Sets (v6.0) 6.637E-5 5.065E-3 4.054E-2
1.114E-1
 2 26
22 18786252-Table4 Human Breast Liu08 26genes GeneSigDB 6.637E-5 5.065E-3 4.054E-2
1.114E-1
 2 26
23 M1594 Genes specifically up-regulated in FL5.12 cells (pro-B lymphocyte) by camptothecin [PubChem=2538]. MSigDB C2: CGP Curated Gene Sets (v6.0) 7.715E-5 5.632E-3 4.508E-2
1.295E-1
 2 28
24 M11405 Candidate genes in the regions of copy number loss in gastric cancer cell lines. MSigDB C2: CGP Curated Gene Sets (v6.0) 8.285E-5 5.647E-3 4.520E-2
1.391E-1
 2 29
25 15140256-Table1 Human Colon VanErk04 36genes GeneSigDB 8.874E-5 5.647E-3 4.520E-2
1.490E-1
 2 30
26 M5520 Genes down-regulated and displaying decreased copy number in glioblastoma samples. MSigDB C2: CGP Curated Gene Sets (v6.0) 9.484E-5 5.647E-3 4.520E-2
1.592E-1
 2 31
27 M9229 Genes down-regulated in CD8 T cells at day 8 after LCMV infection: untreated versus interferon alpha. MSigDB C7: Immunologic Signatures (v6.0) 9.976E-5 5.647E-3 4.520E-2
1.675E-1
 3 200
28 12136251-table5 Human Liver Li02 36genes GeneSigDB 1.011E-4 5.647E-3 4.520E-2
1.698E-1
 2 32
29 14695345-Table1a Mouse Viral Politi04 40genes UpRegulated GeneSigDB 1.011E-4 5.647E-3 4.520E-2
1.698E-1
 2 32
30 M7404 Genes down-regulated in immortalized cell lines. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.076E-4 5.647E-3 4.520E-2
1.807E-1
 2 33
31 18593912-Table1 Mouse StemCell Shachaf08 35genes GeneSigDB 1.076E-4 5.647E-3 4.520E-2
1.807E-1
 2 33
32 15741219-Table3 Human StemCell Roth05 33genes GeneSigDB 1.076E-4 5.647E-3 4.520E-2
1.807E-1
 2 33
33 15548366-Table3 Mouse Bladder Yao04 37genes GeneSigDB 1.212E-4 6.156E-3 4.927E-2
2.035E-1
 2 35
34 15896717-Table7 Human Leukemia Bal05 36genes GeneSigDB 1.283E-4 6.156E-3 4.927E-2
2.155E-1
 2 36
35 M1636 Genes in cluster 3: delayed up-regulation in HFW cells (fibroblast) by sodium arsenite [PubChem=26435]. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.283E-4 6.156E-3 4.927E-2
2.155E-1
 2 36
36 M2370 Oligodendrocyte core differentiation genes: up-regulated in Oli-neo cells (oligodendroglial precursor) at 10 h after treatment with PD174265, dexamethasone or isotretinoin [PubChem=4709, 5743, 5282379]. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.587E-4 7.402E-3
5.924E-2
2.665E-1
 2 40
37 15606925-Table3 Human Breast Bieche04 47genes GeneSigDB 2.103E-4 9.542E-3
7.637E-2
3.530E-1
 2 46
38 17638893-Table1 Human Breast Larsson07 47genes GeneSigDB 2.196E-4 9.701E-3
7.764E-2
3.686E-1
 2 47
39 18354499-Table3 Mouse Liver Knutson08 68genes GeneSigDB 2.690E-4 1.158E-2
9.268E-2
4.516E-1
 2 52
40 18221536-Table1 Human Breast Roll08 64genes GeneSigDB 3.010E-4 1.247E-2
9.984E-2
5.054E-1
 2 55
41 16705456-Table2 Human Leukemia Cao06 56genes GeneSigDB 3.121E-4 1.247E-2
9.984E-2
5.239E-1
 2 56
42 19530251 suppinfo4 Human Breast Rozenchan09 81genes GeneSigDB 3.121E-4 1.247E-2
9.984E-2
5.239E-1
 2 56
43 20103679-ST3-B Human Breast Wood10 416genes GeneSigDB 3.362E-4 1.313E-2
1.051E-1
5.644E-1
 3 302
44 M2086 Genes up-regulated in ITNK cells (T-lymphocyte progenitors (DN3 cells) reprogrammed to natural killer (NK) cells by ablation of BCL11B [GeneID=64919] gene), compared to the parental DN3 cells. MSigDB C2: CGP Curated Gene Sets (v6.0) 3.527E-4 1.337E-2
1.070E-1
5.922E-1
 3 307
45 20548326-Table4 Human Stomach Bonelli10 61genes GeneSigDB 3.583E-4 1.337E-2
1.070E-1
6.016E-1
 2 60
46 M4493 Genes whose promoters were bound by E2F1 and E2F4 [GeneID=1869;1874] in the primary fibroblasts WI-38, by ChIP on chip assay. MSigDB C2: CGP Curated Gene Sets (v6.0) 3.703E-4 1.352E-2
1.082E-1
6.218E-1
 2 61
47 M1322 Genes down-regulated in 10T1/2 cells (multipotent mesoderma) by expression of SHH [GeneID=6469]. MSigDB C2: CGP Curated Gene Sets (v6.0) 4.077E-4 1.456E-2
1.166E-1
6.845E-1
 2 64
48 12623842-Table2 Human BoneMarrow Magrangeas03 20genes GeneSigDB 4.335E-4 1.516E-2
1.214E-1
7.279E-1
 2 66
49 19695104-AF2 Human Breast Lin09 128genes GeneSigDB 4.738E-4 1.623E-2
1.299E-1
7.955E-1
 2 69
50 17638893-SuppTable5 Human Breast Larsson07 71genes GeneSigDB 5.016E-4 1.684E-2
1.348E-1
8.422E-1
 2 71
Show 45 more annotations

14: Coexpression Atlas [Display Chart] 11 input genes in category / 918 annotations before applied cutoff / 21829 genes in category

No results to display

15: Computational [Display Chart] 8 input genes in category / 81 annotations before applied cutoff / 10037 genes in category

No results to display

16: MicroRNA [Display Chart] 11 input genes in category / 384 annotations before applied cutoff / 72241 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 hsa-miR-23b-3p:Functional MTI Functional MTI miRTarbase 1.410E-5 5.413E-3 3.535E-2 5.413E-3 3 322
2 hsa-miR-193a-3p:Non-Functional MTI Non-Functional MTI miRTarbase 1.695E-4 1.373E-2
8.962E-2
6.510E-2
 2 128
3 hsa-miR-99a-5p:Functional MTI Functional MTI miRTarbase 1.830E-4 1.373E-2
8.962E-2
7.028E-2
 2 133
4 TTGGAGA,MIR-519E:MSigDB TTGGAGA,MIR-519E:MSigDB MSigDB 1.886E-4 1.373E-2
8.962E-2
7.241E-2
 2 135
5 TTGGAGA,MIR-515-5P:MSigDB TTGGAGA,MIR-515-5P:MSigDB MSigDB 1.886E-4 1.373E-2
8.962E-2
7.241E-2
 2 135
6 hsa-miR-1469:mirSVR lowEffct hsa-miR-1469:mirSVR nonconserved lowEffect-0.1-0.5 MicroRNA.org 2.145E-4 1.373E-2
8.962E-2
8.236E-2
 2 144
7 hsa-miR-622:PITA hsa-miR-622:PITA TOP PITA 6.275E-4 3.109E-2
2.030E-1
2.409E-1
 2 247
8 hsa-miR-100-5p:Functional MTI Functional MTI miRTarbase 6.478E-4 3.109E-2
2.030E-1
2.488E-1
 2 251
9 hsa-miR-6742-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 9.529E-4 3.368E-2
2.199E-1
3.659E-1
 2 305
10 hsa-miR-450a:mirSVR highEffct hsa-miR-450a:mirSVR conserved highEffect-0.5 MicroRNA.org 1.041E-3 3.368E-2
2.199E-1
3.999E-1
 2 319
11 hsa-miR-10b-5p:Functional MTI Functional MTI miRTarbase 1.067E-3 3.368E-2
2.199E-1
4.098E-1
 2 323
12 hsa-miR-4283:mirSVR highEffct hsa-miR-4283:mirSVR nonconserved highEffect-0.5 MicroRNA.org 1.265E-3 3.368E-2
2.199E-1
4.857E-1
 2 352
13 hsa-miR-5089-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.410E-3 3.368E-2
2.199E-1
5.416E-1
 2 372
14 hsa-miR-181b-5p:Functional MTI Functional MTI miRTarbase 1.433E-3 3.368E-2
2.199E-1
5.503E-1
 2 375
15 hsa-miR-1225-5p:mirSVR highEffct hsa-miR-1225-5p:mirSVR nonconserved highEffect-0.5 MicroRNA.org 1.556E-3 3.368E-2
2.199E-1
5.975E-1
 2 391
16 hsa-miR-6513-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.564E-3 3.368E-2
2.199E-1
6.005E-1
 2 392
17 hsa-miR-638:mirSVR lowEffct hsa-miR-638:mirSVR nonconserved lowEffect-0.1-0.5 MicroRNA.org 1.611E-3 3.368E-2
2.199E-1
6.188E-1
 2 398
18 TGCACTT,MIR-519B:MSigDB TGCACTT,MIR-519B:MSigDB MSigDB 1.800E-3 3.368E-2
2.199E-1
6.911E-1
 2 421
19 TGCACTT,MIR-519A:MSigDB TGCACTT,MIR-519A:MSigDB MSigDB 1.800E-3 3.368E-2
2.199E-1
6.911E-1
 2 421
20 TGCACTT,MIR-519C:MSigDB TGCACTT,MIR-519C:MSigDB MSigDB 1.800E-3 3.368E-2
2.199E-1
6.911E-1
 2 421
21 hsa-miR-4300:mirSVR highEffct hsa-miR-4300:mirSVR nonconserved highEffect-0.5 MicroRNA.org 1.842E-3 3.368E-2
2.199E-1
7.074E-1
 2 426
22 hsa-miR-544:PITA hsa-miR-544:PITA TOP PITA 1.981E-3 3.457E-2
2.257E-1
7.605E-1
 2 442
23 hsa-miR-10a-5p:Functional MTI Functional MTI miRTarbase 2.170E-3 3.594E-2
2.347E-1
8.332E-1
 2 463
24 hsa-miR-1224-3p:mirSVR highEffct hsa-miR-1224-3p:mirSVR nonconserved highEffect-0.5 MicroRNA.org 2.291E-3 3.594E-2
2.347E-1
8.797E-1
 2 476
25 TGCACGA,MIR-517C:MSigDB TGCACGA,MIR-517C:MSigDB MSigDB 2.434E-3 3.594E-2
2.347E-1
9.346E-1
 1 16
26 TGCACGA,MIR-517A:MSigDB TGCACGA,MIR-517A:MSigDB MSigDB 2.434E-3 3.594E-2
2.347E-1
9.346E-1
 1 16
27 hsa-miR-1268:PITA hsa-miR-1268:PITA TOP PITA 2.889E-3 4.109E-2
2.683E-1
1.000E0
 1 19
Show 22 more annotations

17: Drug [Display Chart] 11 input genes in category / 4132 annotations before applied cutoff / 22841 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 ctd:C000602704 UF010 compound CTD 4.719E-13 1.950E-9 1.736E-8 1.950E-9 5 25
2 CID000126312 AC1L2Q3W Stitch 2.120E-10 4.081E-7 3.634E-6 8.759E-7 4 22
3 CID005287969 flavopiridol Stitch 2.963E-10 4.081E-7 3.634E-6 1.224E-6 6 216
4 CID005289419 SU9516 Stitch 1.701E-9 1.757E-6 1.565E-5 7.029E-6 4 36
5 ctd:C100805 DIBA-1 CTD 2.905E-9 2.401E-6 2.138E-5 1.200E-5 3 7
6 CID000499953 phorbol-13-acetate Stitch 3.513E-9 2.419E-6 2.154E-5 1.451E-5 6 326
7 ctd:D002166 Camptothecin CTD 7.767E-9 4.569E-6 4.068E-5 3.209E-5 5 163
8 ctd:C500026 palbociclib CTD 9.881E-9 4.569E-6 4.068E-5 4.083E-5 5 171
9 ctd:C107875 6-(methylamino)pyrido(3,4-d)pyrimidine CTD 9.952E-9 4.569E-6 4.068E-5 4.112E-5 3 10
10 ctd:C017461 lead nitrate CTD 2.575E-8 1.064E-5 9.472E-5 1.064E-4 5 207
11 ctd:D008012 Lidocaine CTD 3.292E-8 1.237E-5 1.101E-4 1.360E-4 4 74
12 CID000157806 N-benzyl-N-hydroxy-5-phenylpentamide Stitch 1.464E-7 5.016E-5 4.466E-4 6.048E-4 3 23
13 ctd:D019438 Ritonavir CTD 1.578E-7 5.016E-5 4.466E-4 6.520E-4 4 109
14 ctd:C483690 apo-14'-carotenoic acid CTD 2.109E-7 6.189E-5 5.511E-4 8.712E-4 2 2
15 ctd:D012835 Silver Nitrate CTD 2.247E-7 6.189E-5 5.511E-4 9.284E-4 4 119
16 CID000164136 Bhpp Stitch 2.415E-7 6.237E-5 5.553E-4 9.979E-4 3 27
17 ctd:C000594117 ON123300 CTD 4.090E-7 9.941E-5 8.851E-4 1.690E-3 3 32
18 CID009547890 N6-9 Stitch 4.932E-7 1.132E-4 1.008E-3 2.038E-3 3 34
19 CID006444166 Citropeptin Stitch 6.324E-7 1.136E-4 1.012E-3 2.613E-3 2 3
20 ctd:C024534 vitamin k5 CTD 6.324E-7 1.136E-4 1.012E-3 2.613E-3 2 3
21 CID006449925 A83586C Stitch 6.324E-7 1.136E-4 1.012E-3 2.613E-3 2 3
22 CID000157711 20(R)-ginsenoside Rg2 Stitch 6.324E-7 1.136E-4 1.012E-3 2.613E-3 2 3
23 ctd:C510786 5-nitroso-8-quinolinol CTD 6.324E-7 1.136E-4 1.012E-3 2.613E-3 2 3
24 CID000159727 ginsenoside Rg3 Stitch 8.130E-7 1.400E-4 1.246E-3 3.359E-3 3 40
25 CID000119307 ginsenoside Rh2 Stitch 1.166E-6 1.927E-4 1.716E-3 4.818E-3 3 45
26 CID010373670 gypenoside XVII Stitch 1.264E-6 1.970E-4 1.754E-3 5.225E-3 2 4
27 CID000445722 AC1L9IGO Stitch 1.287E-6 1.970E-4 1.754E-3 5.318E-3 4 184
28 ctd:D006918 Hydroxyurea CTD 2.437E-6 3.596E-4 3.202E-3 1.007E-2 4 216
29 CID006438325 AC1O5PH2 Stitch 2.801E-6 3.991E-4 3.554E-3 1.157E-2 3 60
30 CID000005097 NSC683246 Stitch 3.349E-6 4.612E-4 4.107E-3 1.384E-2 4 234
31 ctd:C497101 2-hydroxy-9-cis-octadecenoic acid CTD 4.422E-6 5.669E-4 5.048E-3 1.827E-2 2 7
32 CID000073292 fascaplysin Stitch 4.422E-6 5.669E-4 5.048E-3 1.827E-2 2 7
33 CID000216345 Nutlin Stitch 4.665E-6 5.669E-4 5.048E-3 1.928E-2 3 71
34 ctd:C077990 alvocidib CTD 4.665E-6 5.669E-4 5.048E-3 1.928E-2 3 71
35 ctd:C545990 BMS 754807 CTD 5.895E-6 6.766E-4 6.024E-3 2.436E-2 2 8
36 CID000061565 erionite Stitch 5.895E-6 6.766E-4 6.024E-3 2.436E-2 2 8
37 ctd:C403899 HS 1030 CTD 7.577E-6 8.461E-4 7.534E-3 3.131E-2 2 9
38 CID004369285 BIA 3-335 Stitch 8.615E-6 9.367E-4 8.341E-3 3.560E-2 3 87
39 ctd:C010302 aspidin BB CTD 9.468E-6 9.781E-4 8.709E-3 3.912E-2 2 10
40 ctd:C403900 HS 1183 CTD 9.468E-6 9.781E-4 8.709E-3 3.912E-2 2 10
41 ctd:C043867 cicaprost CTD 1.157E-5 1.166E-3 1.038E-2 4.781E-2 2 11
42 ctd:C011363 terephthalic acid CTD 1.388E-5 1.366E-3 1.216E-2
5.735E-2
 2 12
43 ctd:C553817 7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one CTD 1.605E-5 1.473E-3 1.312E-2
6.631E-2
 3 107
44 CID005317623 20(S)-Propanaxidiol Stitch 1.640E-5 1.473E-3 1.312E-2
6.776E-2
 2 13
45 ctd:C044985 1',2'-dihydrorotenone CTD 1.640E-5 1.473E-3 1.312E-2
6.776E-2
 2 13
46 CID006441009 ginsenoside Rg2 Stitch 1.640E-5 1.473E-3 1.312E-2
6.776E-2
 2 13
47 CID000168092 C10E5 Stitch 1.913E-5 1.613E-3 1.436E-2
7.903E-2
 2 14
48 ctd:C031938 calmidazolium CTD 1.913E-5 1.613E-3 1.436E-2
7.903E-2
 2 14
49 CID000098312 xanthommatin Stitch 1.913E-5 1.613E-3 1.436E-2
7.903E-2
 2 14
50 ctd:C059041 calyculin A CTD 1.992E-5 1.646E-3 1.466E-2
8.231E-2
 3 115
Show 45 more annotations

18: Disease [Display Chart] 11 input genes in category / 866 annotations before applied cutoff / 16205 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 C0023827 liposarcoma DisGeNET Curated 1.249E-6 5.700E-4 4.185E-3 1.082E-3 4 130
2 C0334634 Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse DisGeNET Curated 1.717E-6 5.700E-4 4.185E-3 1.487E-3 5 343
3 C1867288 Retinomas (translucent, grayish retinal mass protruding into the vitreous) DisGeNET BeFree 2.512E-6 5.700E-4 4.185E-3 2.175E-3 2 4
4 C0205824 Liposarcoma, Dedifferentiated DisGeNET Curated 2.633E-6 5.700E-4 4.185E-3 2.280E-3 3 42
5 C0030354 Papilloma DisGeNET Curated 6.672E-6 8.703E-4 6.390E-3 5.778E-3 4 198
6 C0018790 Cardiac Arrest DisGeNET Curated 6.807E-6 8.703E-4 6.390E-3 5.895E-3 4 199
7 C0206650 Fibroadenoma DisGeNET Curated 7.035E-6 8.703E-4 6.390E-3 6.092E-3 3 58
8 C0206655 Alveolar rhabdomyosarcoma DisGeNET Curated 1.138E-5 1.232E-3 9.047E-3 9.858E-3 3 68
9 C0278704 Malignant Childhood Neoplasm DisGeNET BeFree 2.001E-5 1.926E-3 1.414E-2 1.733E-2 3 82
10 C0032019 Pituitary Neoplasms DisGeNET Curated 2.236E-5 1.936E-3 1.421E-2 1.936E-2 4 269
11 C3179349 Gastrointestinal Stromal Sarcoma DisGeNET BeFree 3.795E-5 2.988E-3 2.194E-2 3.287E-2 2 14
12 C1510420 Cavitation DisGeNET BeFree 8.735E-5 5.942E-3 4.362E-2
7.565E-2
 2 21
13 C0006413 Burkitt Lymphoma DisGeNET Curated 9.534E-5 5.942E-3 4.362E-2
8.256E-2
 4 390
14 C1336077 Sporadic Burkitt's lymphoma DisGeNET BeFree 9.605E-5 5.942E-3 4.362E-2
8.318E-2
 2 22
15 C0278996 Cancer of Head and Neck DisGeNET Curated 1.342E-4 6.974E-3
5.120E-2
1.162E-1
 4 426
16 C0220611 childhood rhabdomyosarcoma DisGeNET BeFree 1.457E-4 6.974E-3
5.120E-2
1.262E-1
 2 27
17 C1136084 Plasma cell dyscrasia DisGeNET BeFree 1.568E-4 6.974E-3
5.120E-2
1.358E-1
 2 28
18 C3489413 Lipomatosis, Multiple DisGeNET Curated 1.568E-4 6.974E-3
5.120E-2
1.358E-1
 2 28
19 C1332850 Cardiac Lymphoma DisGeNET BeFree 1.568E-4 6.974E-3
5.120E-2
1.358E-1
 2 28
20 C0206686 Adrenocortical carcinoma DisGeNET Curated 1.611E-4 6.974E-3
5.120E-2
1.395E-1
 3 165
21 C1861305 TARSAL-CARPAL COALITION SYNDROME DisGeNET Curated 1.729E-4 7.099E-3
5.212E-2
1.497E-1
 3 169
22 C0334663 Histiocytic sarcoma DisGeNET BeFree 1.803E-4 7.099E-3
5.212E-2
1.562E-1
 2 30
23 C1512981 Mammary Tumorigenesis DisGeNET BeFree 1.982E-4 7.462E-3
5.479E-2
1.716E-1
 3 177
24 C1704423 Milroy Disease DisGeNET Curated 2.754E-4 9.937E-3
7.296E-2
2.385E-1
 2 37
25 C0242363 Islet Cell Tumor DisGeNET BeFree 2.906E-4 9.963E-3
7.315E-2
2.517E-1
 2 38
26 C0280785 Diffuse Astrocytoma DisGeNET BeFree 3.386E-4 9.963E-3
7.315E-2
2.932E-1
 2 41
27 C0023484 Leukemia, Plasma Cell DisGeNET BeFree 3.386E-4 9.963E-3
7.315E-2
2.932E-1
 2 41
28 C1266129 Atypical Lipoma DisGeNET BeFree 3.726E-4 9.963E-3
7.315E-2
3.227E-1
 2 43
29 C0027766 Nervous System Neoplasms DisGeNET Curated 3.902E-4 9.963E-3
7.315E-2
3.379E-1
 2 44
30 C0677055 CARCINOMA OF VULVA DisGeNET BeFree 4.082E-4 9.963E-3
7.315E-2
3.535E-1
 2 45
31 C0027533 Neck Neoplasms DisGeNET BeFree 4.082E-4 9.963E-3
7.315E-2
3.535E-1
 2 45
32 C0010633 Cystadenoma DisGeNET BeFree 5.041E-4 9.963E-3
7.315E-2
4.366E-1
 2 50
33 C2349952 Oropharyngeal Carcinoma DisGeNET BeFree 6.100E-4 9.963E-3
7.315E-2
5.283E-1
 2 55
34 C0851887 Adenoviral infections DisGeNET BeFree 6.551E-4 9.963E-3
7.315E-2
5.673E-1
 2 57
35 C0205854 Glandular Neoplasms DisGeNET BeFree 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
36 cv:C1835044 Cutaneous malignant melanoma 2 Clinical Variations 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
37 C1334266 Intraurothelial Neoplasia DisGeNET BeFree 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
38 C2675993 Pancreatic squamous cell carcinoma DisGeNET Curated 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
39 cv:C0035335 Retinoblastoma Clinical Variations 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
40 OMIN:180200 RETINOBLASTOMA; RB1 OMIM 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
41 OMIN:155755 MELANOMA-ASTROCYTOMA SYNDROME OMIM 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
42 C0008628 Chromosome Deletion DisGeNET Curated 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
43 C0347493 Cervix adenomatous polyp DisGeNET BeFree 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
44 C0740971 anal cancer squamous cell DisGeNET BeFree 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
45 OMIN:606719 MELANOMA-PANCREATIC CANCER SYNDROME OMIM 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
46 C1867289 Retinal calcification DisGeNET Curated 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
47 C0008298 Polyp in nasopharynx DisGeNET BeFree 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
48 C0339304 Neoplasm of cornea DisGeNET BeFree 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
49 cv:C0149925 Small cell cancer of the lung Clinical Variations 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
50 C1332608 Astrocytoma of brain stem DisGeNET BeFree 6.788E-4 9.963E-3
7.315E-2
5.878E-1
 1 1
Show 45 more annotations